Dr Gaedigk has a long-standing interest in pharmacogenetics and genomics. She has extensively worked with Cytochrome P450s and characterized their genetic variation in many ethnically diverse adult and pediatric populations in clinical and basic research settings. She is a leading expert in the pharmacogenetics of CYP2D6 and the implementation of genotype data into clinical practice. Dr Gaedigk is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and key contributor to CYP2D6 gene/drug pair dosing guidelines. She also leads a new PGRN resource, the Pharmacogene Variation (PharmVar) Consortium (www.pgrn.org/pharmvar.html and www.PharmVar.org). At the center of the Consortium is the PharmVar database, which houses pharmacogene variation that focuses on haplotype structure (star alleles). One particular focus of her current work involves close collaborations with the PharmGKB and CPIC to unify and standardize pharmacogene variation designation and translation into phenotype to facilitate the interpretation of pharmacogenetic test results to guide precision medicine. | Director Pharmacogenetics Core Laboratory, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children’s Mercy Kansas City. Professor School of Medicine, University of Missouri-Kansas City. [email protected] Full Profile |